-1752957036180.webp&w=3840&q=75)
2025 NOSCM | Innovations in Thoracic Oncology in 20 Years
Overview
Dr. David Carbone outlined lung cancer treatment advances from 1990–2022, with survival gains from chemo, targeted therapy, and immunotherapy. He cited ALK-targeted success and 20–21% five-year survival with immunotherapy. Emphasis was placed on early detection and future cures for driver mutations.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
David Carbone, MD, PhD
Date of Release
July 20th, 2025
-1755988066641.webp&w=3840&q=75)
-1755987918967.webp&w=3840&q=75)